Syndax Pharmaceuticals Free Cash Flow Over Time
| SNDX Stock | USD 13.47 1.47 9.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Syndax Pharmaceuticals Performance and Syndax Pharmaceuticals Correlation. Syndax |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.64) | Revenue Per Share 0.195 | Quarterly Revenue Growth 332.974 | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Analysis
Compare Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Free Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COGT | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | (21.9 M) | (26.7 M) | (33 M) | (41.5 M) | (35.9 M) | (60.5 M) | (125.5 M) | (156.4 M) | (148.6 M) |
| CGEM | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (20.9 M) | (29.8 M) | (44 M) | (127.8 M) | (134.5 M) | (127.8 M) |
| KALV | (1.9 M) | (1.9 M) | (1.9 M) | (4.9 M) | (6.5 M) | (13.2 M) | (23.8 M) | 9.1 M | (37.4 M) | (45 M) | (30.3 M) | (79.1 M) | (76.5 M) | (89.7 M) | (85.2 M) |
| MRSN | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | 30.5 M | (43.8 M) | (56.6 M) | (68.3 M) | (75.2 M) | (140.6 M) | (51.6 M) | (171.1 M) | (162.5 M) |
| PLRX | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (30.7 M) | (3.7 M) | (38.8 M) | (77.4 M) | (96.4 M) | (117.3 M) | (111.4 M) |
| RVMD | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (286 K) | (52.2 M) | (103 M) | (153.7 M) | (235.2 M) | (358.3 M) | (340.4 M) |
| VRDN | (6.3 M) | (6.3 M) | (6.3 M) | (1.2 M) | (2.5 M) | (7 M) | (7.2 M) | (28.4 M) | (27.3 M) | (36.1 M) | (29.8 M) | (54.9 M) | (94.6 M) | (185.1 M) | (175.8 M) |
| INZY | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (18.9 M) | (36.5 M) | (48.5 M) | (58.2 M) | (71 M) | (67.4 M) |
| AVTE | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (7.9 M) | (27.6 M) | (39.3 M) | (56.9 M) | (54.1 M) |
| KROS | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | (16.3 M) | (37.2 M) | (63.2 M) | (71.3 M) | (127 M) | (120.6 M) |
| MLYS | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (14.6 M) | (29.2 M) | (81.2 M) | (77.1 M) |
| REPL | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (16.1 M) | (28 M) | (67.1 M) | (63.8 M) | (84.5 M) | (130.3 M) | (191.1 M) | (181.6 M) |
| PCVX | (16.2 K) | (16.2 K) | (16.2 K) | (16.2 K) | (16.2 K) | (16.2 K) | (16.2 K) | (16.2 K) | (32.2 M) | (48.3 M) | (47.8 M) | (127.9 M) | (176.4 M) | (364.7 M) | (346.4 M) |
| LRMR | (28.3 M) | (28.3 M) | (28.3 M) | (28.3 M) | (28.3 M) | (60.1 M) | (52.6 M) | (43.8 M) | (51.6 M) | (22.8 M) | (42.3 M) | (42.4 M) | (27.7 M) | (33.6 M) | (35.3 M) |
| MRUS | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (17.9 M) | (25.3 M) | (27.6 M) | (45.8 M) | (50.5 M) | (65.6 M) | (81.2 M) | (60.5 M) | (157.5 M) | (146.2 M) | (138.9 M) |
| STRO | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (40.4 M) | 11.1 M | (68.5 M) | (74.9 M) | (97 M) | (4.3 M) | (115.9 M) | (110.1 M) |
| CYTK | (28.9 M) | (46 M) | (33.6 M) | (8.3 M) | (45.9 M) | 4.3 M | 35.4 M | (104.6 M) | (102.1 M) | (93.5 M) | (2.1 M) | (191.4 M) | (310.9 M) | (415.7 M) | (395 M) |
| EWTX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (14.8 M) | (34.2 M) | (58.2 M) | (97.7 M) | (92.8 M) |
| DYN | 341 M | (262 M) | (44 M) | 77 M | (62 M) | (181 M) | 350 M | 361 M | (4.3 M) | (13.5 M) | (47.7 M) | (123.2 M) | (156.7 M) | (188.9 M) | (179.4 M) |
Syndax Pharmaceuticals and related stocks such as Cogent Biosciences, Cullinan Oncology LLC, and Kalvista Pharmaceuticals Free Cash Flow description
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.My Equities
My Current Equities and Potential Positions
| Syndax Pharmaceuticals | SNDX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 13.47
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.